Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Tobramycin nebulised		NHS England Commissioned for Cystic Fibrosis only, new patients
Tofacitinib (Xeljanz®)	TA547 - Tofacitinib for moderately to severely active ulcerative colitis
Topotecan capsules	TA184 - Topotecan for the treatment of relapsed small-cell lung cancer	For hospital use only
Tramadol
Trametinib	TA396 - Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Tranexamic acid injection		Hospital use only
Trastuzumab emtansine	TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Trastuzumab infusion	TA257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA208 - Trastuzumab for the treatment of HER2-positive metastatic gastric cancer TA107 - Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer	Funding approval should be sought prior to initiation
Treosulfan capsules		National CDF list
Treosulfan injection		For hospital use only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.